These findings suggest that the AIM2 inflammasome activation and resulting IL-1β release after stroke could lead to plaque destabilization and atherothrombosis via activation of plaque-degrading MMPs and subsequent factor XIIa deposition. The gene discussed is AIM2; the disease is stroke disorder.